As­traZeneca com­mits $57.5M to seed An­ti­calin R&D pact with Pieris, a biotech on a roll

Boston-based Pieris Phar­ma­ceu­ti­cals has rolled out its sec­ond big-mon­ey col­lab­o­ra­tion in the last four months, this time reel­ing in Big Phar­ma play­er As­traZeneca, which wants …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER